The Medical Management of Gender Dysphoric, Gender Fluid, Gender Nonconforming, Gender Queer, Nonbinary, and Transgender Patients: One Clinic’s Approach
- 19 Downloads
Purpose of the Review
To present a practical guide to the care and treatment of gender diverse patients with and without gender dysphoria.
Gender diverse patients experience considerable discrimination in the healthcare system and often cannot obtain basic medical care or specialized hormonal management. There is scant evidence to guide the clinician in making the care decisions of gender diverse patients. Although some guidelines exist, these often lack the rationale and practical considerations that are necessary for the respectful care of this oppressed community.
Providing healthcare to gender diverse patients, with and without gender dysphoria, and their partners can be challenging. The current article provides practical guidance and a review of the literature to support that guidance.
KeywordsTransgender Gender dysphoria Gender diverse Stigma in healthcare Nonbinary
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Research Involving Human Participants and/or Animals
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390–400. https://doi.org/10.1016/S0140-6736(16)00683-8 Excellent presentation of the problems gender diverse patients face interacting with the healthcare system. CrossRefPubMedGoogle Scholar
- 5.Snelgrove JW, Jasudavisius AM, Rowe BW, Head EM, Bauer GR. “Completely out-at-sea” with “two-gender medicine”: a qualitative analysis of physician-side barriers to providing healthcare for transgender patients. BMC Health Serv Res. 2012;12:110. https://doi.org/10.1186/1472-6963-12-110.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.The World Professional Association for Transgender Health (WPATH). Standards of care for the health of transsexual, transgender, and gender nonconforming people, Vol. 7. https://www.wpath.org/media/cms/Documents/Web%20Transfer/SOC/Standards%20of%20Care%20V7%20-%202011%20WPATH.pdf. Downloaded August 12, 2018.
- 7.Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903. https://doi.org/10.1210/jc.2017-01658.CrossRefPubMedGoogle Scholar
- 8.Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people; 2nd edition. Deutsch MB, ed. June 2016. Available at http://www.transhealth.ucsf.edu/trans?page=guidelines-home Downloaded 8/12/18.
- 10.https://en.wikipedia.org/wiki/Transgender. Downloaded August 12. 2018.
- 12.• Goldstein Z, Corneil TA, Greene DN. When gender identity doesn’t equal sex recorded at birth: the role of the laboratory in providing effective healthcare to the transgender community. Clin Chem. 2017;63(8):1342–52. https://doi.org/10.1373/clinchem.2016.258780 Explains the inherent bias that gender diverse patients face by omitting and ignoring evidence-based changes in clinical laboratory values associated with gender transition. CrossRefPubMedGoogle Scholar
- 19.Moser C. (2008), The DSM-V and the gender diagnoses. Society for Sex Therapy and Research Newsletter, 25(2), 4-5. [WWW document] URL http://www.sstarnet.org/download/News2008Jul.pdf
- 20.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.Google Scholar
- 23.Murphy TF. Should mental health screening and psychotherapy be required prior to body modification for gender expression? AMA J Ethics. 2016;18(11):1079–85. https://doi.org/10.1001/journalofethics.2016.18.11.ecas2-1611.CrossRefPubMedGoogle Scholar
- 24.Klaver M, de Blok CJM, Wiepjes CM, Nota NM, Dekker MJHJ, de Mutsert R, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol. 2018;178(2):165–73. https://doi.org/10.1530/EJE-17-0496.CrossRefGoogle Scholar
- 27.Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause. 2016;23(6):593–9. https://doi.org/10.1097/GME.0000000000000611.CrossRefPubMedGoogle Scholar
- 29.Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://doi.org/10.1001/jama.288.3.321.CrossRefGoogle Scholar
- 32.Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017;102(7):2349–55. https://doi.org/10.1210/jc.2017-00359.CrossRefPubMedGoogle Scholar
- 33.Handelsman, DJ. Androgen physiology, pharmacology and abuse. In Endotext [Internet] De Groot LJ, Chrousos G, Dungan K, et al., editors. https://www.ncbi.nlm.nih.gov/books/NBK279000/
- 35.Kim JH, Baek MJ, Sun HY, Lee B, Li S, Khandwala Y, et al. Chung BI Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS One. 2018;13(10):e0203479. https://doi.org/10.1371/journal.pone.0203479 eCollection 2018.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Sex Med. 2011;8(3):872–84. https://doi.org/10.1111/j.1743-6109.2010.02157.x.CrossRefGoogle Scholar
- 43.Mayer KH, Krakower D. Administration of pre-exposure prophylaxis against HIV infection. Uptodate https://www.uptodate.com/contents/administration-of-pre-exposure-prophylaxis-against-hiv-infection. Downloaded 8/25/18.45a
- 47.Wiepjes CM, Vlot MC, Klaver M, Nota NM, de Blok CJ, de Jongh RT, et al. Bone mineral density increases in trans persons after 1 year of hormonal treatment: A Multicenter Prospective Observational Study. J Bone Miner Res. 2017;32(6):1252–60. https://doi.org/10.1002/jbmr.3102.CrossRefPubMedGoogle Scholar
- 50.Adkins BD, Barlow AB, Jack A, Schultenover SJ, Desouki MM, Coogan AC, et al. Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: challenges in detecting dysplasia. Cytopathology. 2018;29(3):281–7. https://doi.org/10.1111/cyt.12525.CrossRefPubMedGoogle Scholar
- 53.Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59. https://doi.org/10.1016/j.jacc.2013.11.005.CrossRefPubMedGoogle Scholar
- 54.Diamond LM. Sexual fluidity: understanding women’s love and desire. Harvard University Press: Cambridge, MA, 2008 333 pp., ISBN: 978-0674032262.Google Scholar